Published online: 2024 April 28.

Research Article

Perspectives on Cirrhosis in Southern Iran: A Temporal Comparative Study from 2009 to 2022

Hassan Askari¹, Sara Shojaei Zarghani², Leila Rahmati¹, Vida Ahmadi i¹, Ali Reza Safarpour i¹,^{*}, Mohammadreza Fattahi^{1,**}, Hossein Kargar Jahromi i²,⁴, Gholam Reza Sivandzadeh i¹,¹

¹Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

² Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

³ Research center for Non-communicable Disease, Jahrom University of Medical Sciences, Jahrom, Iran

⁴ Zoonoses Research Center, Jahrom University of Medical Sciences, Jahrom, Iran

* Corresponding Author: Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. Email: safarpourar@gmail.com

Received 2023 July 4; Revised 2024 March 25; Accepted 2024 April 5.

Abstract

Background: The epidemiology of cirrhosis, a significant public health issue, remains poorly understood in Iran.

Objectives: This study aimed to evaluate the characteristics, etiologies, complications, and outcomes of patients with cirrhosis who were registered in the Shiraz cirrhosis registry in Iran.

Methods: In this descriptive-analytical study, a total of 2937 patients with cirrhosis from 2009 to 2016, and 683 patients from 2017 to 2022 were enrolled at Shahid Motahhari clinic in Shiraz and included in our database. Demographic, clinical, and laboratory data were collected at baseline and every six months thereafter. Mortality, hepatocellular carcinoma, and liver transplantation occurrences were monitored biannually. Statistical differences between groups were assessed using the Mann-Whitney U test, chi-square test, or Fisher's exact test, depending on the data distribution and the nature of the variables.

Results: The average age of patients during the first period was 47.4 ± 21.5 years, and for the second period, it was 54.8 ± 14.1 years. Biochemical levels and the prevalence of most complications were higher in the second period compared to the first. Ascites was the most common complication in the first group (52.1%), while esophageal varices were more prevalent in the second (40.1%). Hepatitis B and C were common among patients, especially in men. Patients registered in the earlier period had higher mortality and liver transplantation rates than those in the later period.

Conclusions: The findings suggest that patients registered in the later period displayed better laboratory and clinical outcomes, likely due to improved management strategies over time. Viral hepatitis B and C were identified as the predominant etiologies among the patients with cirrhosis included in the study.

Keywords: Liver Cirrhosis, Hepatitis, Liver Diseases, Registries, Hepatitis B Vaccines

1. Background

Cirrhosis is a severe, late-stage scarring (fibrosis) of the liver, typically resulting from long-term liver diseases and conditions such as hepatitis, chronic alcoholism, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH) (1). This serious condition is prevalent worldwide and has increasingly become a significant health burden since the 1990s (2). Previous studies indicate that the global prevalence of cirrhosis ranges from 4.5 to 9.5% of the general population (2). However, these rates are likely underestimated, as most patients remain asymptomatic (3).

Cirrhosis was ranked as the 11th leading cause of global mortality in 2016 (4). In 2017, cirrhosis and other chronic liver disorders accounted for 1.42% of all deaths in Iran (5). Additionally, the total number of deaths caused by cirrhosis in Iran gradually increased from 1990 to 2002, then declined by 2015, possibly due to the national hepatitis B virus (HBV) vaccination program (6).

Effective prevention of cirrhosis requires an understanding of its associated risk factors, which

Copyright © 2024, Askari et al. This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

remain inadequately described. Recent developments, such as the availability of treatments for hepatitis C virus (HCV) and HBV, along with increased rates of obesity, NAFLD, NASH, metabolic syndrome, and alcohol consumption, have influenced the epidemiology of cirrhosis (7). Therefore, further studies are needed to better elucidate the risk factors for the development and progression of cirrhosis.

Cirrhosis leads to several complications, including ascites, variceal bleeding, non-bleeding varices, hepatic encephalopathy, hepatorenal syndrome, and spontaneous bacterial peritonitis (SBP) (8). The management of the disease typically focuses on stabilizing the patient's clinical condition, with liver transplantation being the only definitive treatment (9). Despite advances in medical care for cirrhosis patients, the mortality rate from infections, hepatocellular carcinoma, and complications related to cirrhosis remains high (10).

2. Objectives

Currently, there are few long-term studies investigating the characteristics of patients with cirrhosis in Iran. Therefore, this study aimed to: (1), Provide epidemiological data on patients with cirrhosis recorded in our database; (2), elucidate the prevalence and distribution of risk factors, etiologies, and complications associated with cirrhosis among patients; and (3), define the outcomes associated with cirrhosis during the 13-year data registry. These variables were compared between patients registered from 2009 - 2016 and those registered from 2017 - 2022, corresponding with the period of full hepatitis vaccination coverage.

3. Methods

This descriptive-analytical study analyzed the medical records of 3,620 patients diagnosed with cirrhosis, registered at the Shiraz Gastroenterohepatology Research Center, Shahid Motahhari clinic, Iran, between 2009 and 2022. The patients were divided into two groups based on the period of full hepatitis vaccination coverage: Group one consisted of patients registered from 2009 - 2016, and group two consisted of those registered from 2017 -2022. The patients included in this ongoing database span all age groups, with cirrhosis diagnoses confirmed through various techniques, including ultrasound imaging (sonography), fibroscan screening, computed tomography (CT), magnetic resonance imaging (MRI), and liver biopsy, in addition to clinical and biochemical parameters. Eligible subjects are referred to the clinic by

gastroenterologists, where the study's objectives are explained to each patient or their legal guardian before obtaining informed consent. A gastroenterologist subsequently confirms the diagnosis of cirrhosis following a comprehensive examination. After this confirmation, a baseline questionnaire is completed for each patient, capturing demographic, clinical, and laboratory data, disease progression details, history of alcohol and drug exposure, personal and family medical histories, and past surgical procedures. Moreover, complications and outcomes (mortality, hepatocellular carcinoma, and liver transplantation) are documented every six months. Participants are followed up via telephone for data collection, with physician visits recorded. Participants reporting being anv complications or relevant outcomes are requested to share their medical records for uploading into the database. A gastroenterologist is tasked with verifying these records.

Regular alcohol use is defined as individuals who consume alcohol most weeks of the year (11), and current smokers are defined as those who have smoked cigarettes daily over the past six months (12). Data for patients registered during the initial period are evaluated retrospectively without current follow-up, whereas patients registered during the subsequent period are monitored prospectively. The local Ethics Committee of Shiraz University of Medical Sciences has granted ethical approval for the project (IR.SUMS.REC.1394.S200).

3.1. Statistical Analysis

The statistical analysis was conducted using SPSS 26. Continuous parametric and non-parametric variables are reported as means \pm standard deviations (SDs) and medians [interquartile range (IQR)], respectively, while categorical variables are reported as numbers (percentages). The Shapiro-Wilk test was used to assess the normal distribution of the data. Differences between and within groups were analyzed based on data classification, using two statistical methods. For non-parametric data, the Mann-Whitney U test was used, and for categorical variables, the chi-square or Fisher's exact tests were applied. A P-value of < 0.05 was considered significant.

4. Results

Our database contains records of 3,620 patients, with 2 937 participants registered between 2009 and 2016 (group 1), and 683 registered between 2017 and 2022 (group 2). Although no significant differences were found in sex distribution and nationality, significant variations in age and marital status were observed between these two periods (P-value < 0.001) as reported in Table 1. Among participants enrolled in the first period, 84 (2.9%) reported regular alcohol consumption, compared to 90 (13.2%) between 2017 and 2022. Additionally, in the first period, 225 participants (7.7%) were current cigarette smokers, while in the second period, this frequency increased to 198 (28.3%).

 $\mbox{Table 1.}$ Comparison of Demographic Characteristics in Registered Patients with Cirrhosis $^{\rm a,\,b}$

2009 - 2016	2017 - 2022	P-Value ^c
2937	683	-
		0.098
1902 (64.8)	468 (68.5)	
1035 (35.2)	215 (31.5)	
		0.716
2960 (98.2)	596 (98)	
53 (1.8)	12(2)	
		< 0.001
1407 (50.6)	107 (15.9)	
1376 (49.4)	541 (80.4)	
0(0.0)	8 (1.2)	
0(0.0)	17 (2.5)	
		< 0.001
539 (18.3)	20 (3.30)	
263 (8.9)	28 (4.6)	
305 (10.50)	71 (11.7)	
451 (15.30)	147 (24.1)	
750 (25.50)	201 (33.00)	
432 (14.7)	109 (17. 9)	
197 (6.7)	33 (5.4)	
	2009 - 2016 2937 1902 (64.8) 1035 (35.2) 2960 (98.2) 2960 (98.2) 1407 (50.6) 1407 (50.6) 1376 (49.4) 0 (0.0) 0 (0.0) 539 (18.3) 263 (8.9) 305 (10.50) 451 (15.30) 750 (25.50) 432 (14.7) 197 (6.7)	2009-2016 2017-2022 2937 683 1902 (64.8) 468 (68.5) 1035 (35.2) 215 (31.5) 2960 (98.2) 596 (98) 53 (1.8) 12 (2) 1407 (50.6) 107 (15.9) 1376 (49.4) 541 (80.4) 0 (0.0) 8 (1.2) 0 (0.0) 17 (2.5) 539 (18.3) 20 (3.30) 263 (8.9) 28 (4.6) 305 (10.50) 71 (11.7) 451 (15.30) 147 (24.1) 750 (25.50) 201 (33.00) 432 (14.7) 109 (17.9) 197 (6.7) 33 (5.4)

^a Values are expressed as No. (%).

^b Between-group differences were determined using the chi-square test.

^c P-values < 0.05 are significant.

Based on Table 2, it is observed that the baseline serum levels of alanine transaminase, aspartate transaminase, alkaline phosphatase, blood urea nitrogen, bilirubin, prothrombin time, international normalized ratio, and white blood cells were significantly lower (all P-values < 0.001), while the levels of albumin, protein, platelets, and hemoglobin were higher among patients registered during the second period compared to those during the first period.

Among the patients studied, ascites was the most common complication in the first period, whereas esophageal varices were more prevalent in the second period. Except for esophageal varices (34.4% vs. 40.1%, P- value = 0.005), other complications such as ascites (52.1% vs. 31.8%, P-value < 0.001), variceal bleeding (19.9% vs. 15.7%, P-value = 0.012), SBP (14.5% vs. 6.7%, P-value < 0.001), hepatorenal syndrome (8.1% vs. 4.0%, P-value = 0.005), portal vein thrombosis (6.8% vs. 2.6%, P-value = 0.001), and hepatic encephalopathy (31.2% vs. 8.8%, P-value < 0.001) were significantly more common among patients registered during the first period compared to the second period. Additionally, there were higher rates of SBP among men in both periods (Table 3).

In an additional analysis, we assessed the frequency of cirrhosis complications in the population aged under 15 years at two time points. However, none of the complications showed a statistically significant difference between these two time points (Appendix 1 in the Supplementary File).

Between 2009 and 2016, HBV was the most common etiology of cirrhosis, accounting for 20.6% of cases, followed by cryptogenic cirrhosis (20.1%), autoimmune hepatitis (14.1%), and HCV (11.5%). In the subsequent period, the most common etiology was HCV (30.4%), followed by cryptogenic cirrhosis (18.9%), HBV (16.8%), NAFLD/NASH (7.1%), and autoimmune hepatitis (6.8%). Notably, the prevalence of HBV (P-value = 0.030), autoimmune hepatitis (P-value < 0.001), primary sclerosing cholangitis (P-value = 0.001), and Wilson's disease (P-value = 0.010) was significantly higher among patients registered in the first period, whereas HCV (Pvalue < 0.001) and NAFLD/NASH (P-value < 0.001) were more common in the second period. The prevalence of intravenous (IV) drug abuse was significantly higher among patients with HBV (16.1% vs. 8.9%), autoimmune hepatitis (19.4% vs. 8.9%), and NAFLD (25.0% vs. 6.4%) in the first period compared to the second. However, it was lower among patients with HCV (27.3% vs. 50.5%) (Table 4). Males had higher rates of HBV, HCV, and alcoholrelated liver diseases in both study periods compared to females. However, females had higher rates of autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis in the second period compared to males. The sex distributions of autoimmune hepatitis and primary biliary cholangitis differed significantly between the two periods (Table 5).

The comparison of outcomes among registered patients with cirrhosis is presented in Appendix 2 (in Supplementary File). Among patients registered during the first period, 1.348 (45.9%) underwent liver transplantation, and 1.026 (34.9%) died during this time. These proportions were significantly higher than those observed among patients registered during the second period [199 (29.1%) underwent liver transplantation and 81 (11.9%) died; P-value < 0.001]. Notably, post-

Fable 2. Laboratory Parameters of Patients with Cirrhosis at the Time of Admission ^{a, b}					
Parameters	2009 - 2016 (n = 2937)	2017 - 2022 (n = 683)	P – Value ^c		
AST, IU/L	79.00 (46.00 - 152.00)	40.00 (30.00 - 68.00)	< 0.001		
ALT, IU/L	52.00 (30.00 - 107.00)	33.00 (22.00 - 54.00)	< 0.001		
ALP, IU/L	344.00 (228.00 - 564.00)	259.00 (193.50 - 358.50)	< 0.001		
Albumin, g/dL	3.10 (2.70 - 3.60)	3.60 (3.10 - 4.20)	< 0.001		
Protein, g/dL	6.90 (6.10 - 7.60)	7.10 (6.60 - 7.60)	0.003		
Platelet count, 10 ³ /µL	92.00 (54.00 - 155.75)	98.50 (65.75 - 140.00)	0.186		
WBC, µL	6600.00 (4300.00 - 10300.00)	5000.00 (3700.00 - 6700.00)	< 0.001		
INR	1.83 (1.40 - 2.55)	1.23 (1.09 - 1.53)	< 0.001		
РТ	18.00 (15.20 - 21.50)	14.20 (13.00 - 16.40)	< 0.001		
Hb, g/dL	10.60 (9.00 - 12.40)	12.50 (10.60 - 14.30)	< 0.001		
FBS, mg/dL	103.00 (84.00 - 144.00)	103.00 (89.50 - 139.00)	0.133		
Bilirubin total, mg/dL	4.00 (1.90 - 11.56)	1.40 (1.00 - 2.33)	< 0.001		
Bilirubin direct, mg/dL	1.40 (0.60 - 4.70)	0.47 (0.30 - 0.81)	< 0.001		
Creatinine, mg/dL	1.00 (0.70 - 1.60)	1.00 (0.90 - 1.13)	0.760		
BUN, mg/dL	18.00 (11.00 - 34.00)	15.00 (11.00 - 19.22)	< 0.001		

^z Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; FBS, fasting blood glucose; Hb, hemoglobin; INR, international normalized ratio; IQR, interquartile range; PT, prothrombin time; WBC, white blood cells.

^aValues are expressed as median (IQR).

^b Between-group differences in variables were determined using the Mann-Whitney U test.

^c P-values < 0.05 are significant.

transplantation mortality rates were higher among patients registered during the first period compared to the second (P-value < 0.001), with 23.3% (n = 314) and 8.0% (n = 16) of patients who received transplants during the first and second periods, respectively, passing away.

5. Discussion

While researchers in developed countries have extensively studied the epidemiology of liver cirrhosis, unfortunately, this subject has received little focus in developing countries, possibly due to the low quality of available data (6). In this study, we aimed to assess the distribution of risk factors, etiologies, complications, and outcomes associated with cirrhosis among our registered patients.

The investigation of cirrhosis across two time periods revealed a noteworthy reduction in biochemical factors and a decrease in the prevalence of liver diseases during the second period. Data analysis showed that despite vaccination, viral hepatitis remains the most common cause of cirrhosis in both periods, and it was more prevalent among men.

Furthermore, besides the crucial role of vaccination, differences between these periods may be attributed to advancements in disease management and public health measures, where vaccination plays a key role.

Assessing baseline data showed that, despite the higher involvement of older individuals in both groups, the incidence of young people (less than 25 years) was lower in the second group. Initially, studies believed that one of the risk factors for kidney problems, including liver cirrhosis, is age (13). Studies suggest that cirrhosis is more frequently seen after the age of 50 (14) and is also more common in men than in women (8), as reflected in our study data. In this regard, in our study, HBV and HCV were the most common etiologies of cirrhosis, with a higher prevalence among men. This gender disparity may be attributed to a higher frequency of business travel and high-risk behaviors for hepatitis transmission among males compared to females, as supported by previous literature (15). Moreover, it has been observed that men exhibit lower levels of awareness regarding health issues compared to women. Consequently, cirrhosis tends to occur less frequently in women, owing to their lower prevalence of HBV, HCV, and alcohol consumption.

On the other hand, the immune response to vaccines is higher at a younger age; therefore, even if we assume that vaccine administration across different age groups is the same, which it is not, younger individuals still show a better response to the vaccine. In this context, autoimmune hepatitis causes cirrhosis at younger ages,

Complication	2009 - 2016 (n = 2937)	P-Value ^d	2017 - 2022 (n = 683)	P-Value ^d	P-Value
Esophageal varices		0.058		0.900	
Total	1011 (34.4)		274 (40.1)		
Male	678 (67.1)		187 (68.2)		0.005 ^e
Female	333 (32.9)		87 (31.8)		0.710 ^f
Variceal bleeding		0.038		0.877	
Total	583 (19.9)		107 (15.7)		
Male	399 (68.4)		74 (69.2)		0.012 ^e
Female	184 (31.6)		33 (30.8)		0.883 ^f
Ascites		0.261		0.059	
Total	1531 (52.1)		217 (31.8)		
Male	1006 (65.7)		138 (63.6)		< 0.001 ^e
Female	525 (34.3)		9 (36.4)		0.540 ^f
Spontaneous bacterial pertonitis		0.044		0.012	
Total	353 (14.5)		32 (6.7)		
Male	212 (60.1)		15 (46.9)		< 0.001 ^e
Female	141 (39.9)		17 (53.1)		0.147 ^f
Hepatorenal syndrome		0.355		0.526	
Total	237 (8.1)		27 (4.0)		
Male	160 (67.5)		17(63.0)		0.005 ^e
Female	77 (32.5)		10 (37.0)		0.634 ^f
Portal vein thrombosis		0.524		0.864	
Total	201(6.8)		18 (2.6)		
Male	126 (62.7)		12 (66.7)		0.001 ^e
Female	75 (37.3)		6 (33.3)		0.738 ^f
Hepatic encephalopathy		0.178		0.155	
Total	917 (31.2)		60 (8.8)		
Male	610 (66.5)		46 (76.7)		< 0.001 ^e
Female	307 (33.5)		14 (23.3)		0.105 ^f

^a Values are expressed as No. (%).

^b Between-group differences were assessed using the chi-square test.

^c P-values < 0.05 are significant.

^d Comparison of sex distribution in each period.

^e Comparison of total number of complication between two periods.

^f Comparison of sex distribution between two periods.

while other factors such as NAFLD tend to cause cirrhosis at older ages (14).

In this medical registry-based study, it was observed that biochemical tests showed better results in the second period compared to the first. As we know, elevated levels of liver enzymes such as ALT, AST, and alkaline phosphatase, along with increased levels of bilirubin and immunoglobulins and lower levels of albumin, are the most important biomarkers in the diagnosis of cirrhosis. Our study indicated that in the second group, these factors were significantly reduced in patients with cirrhosis compared to the first group, which could impact their mortality. Other studies in our country share a similar view (5, 6). One study showed that deaths due to cirrhosis decreased significantly by 2015, which they believe aligns with the period of maximum coverage of hepatitis B vaccination (6). However, no study has examined the changes in biomarker levels in the years following vaccination compared to the years before, and what we have found in this study opens a window into a new realm of understanding. Nonetheless, the efforts of the Ministry

Variables		Frequency			IV Drug Abusers			
	2009-2016	2017 - 2022	P-Value ^c	2009 - 2016	2017 - 2022	P-Value ^c		
Hepatitis B	604 (20.6)	112 (16.8)	0.030	97 (16.1)	10 (8.9)	0.008		
Hepatitis C	337 (11.5)	202 (30.4)	< 0.001	92 (27.3)	102 (50.5)	< 0.001		
Autoimmune hepatitis	413 (14.1)	45 (6.8)	< 0.001	80 (19.4)	4 (8.9)	0.048		
PBC	69 (2.3)	8 (1.2)	0.074	9 (13.0)	1(12.5)	1.000		
PSC	149 (5.1)	15 (2.3)	0.001	9 (6.0)	0(0.0)	0.596		
NAFLD/NASH	40 (1.4)	47 (7.1)	< 0.001	10 (25.0)	3(6.4)	0.003		
Wilson	87 (3.0)	8 (1.2)	0.010	10 (11.5)	0(0)	0.591		
Alcohol related	71 (2.4)	24 (3.6)	0.083	26 (36.6)	17 (70.8)	0.005		
Hemochromatosis	47 (1.6)	5 (0.8)	0.107	4 (8.5)	1(20.0)	0.379		
Cryptogenic	589 (20.1)	126 (18.9)	0.518	18 (3.0)	12 (9.5)	0.018		

² Abbreviations: PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; NASH, nonalcoholic steatohepatitis; NAFLD, non-alcoholic fatty liver disease. ^a Values are expressed as No. (%).

^b Between-group differences in variables were determined using the chi-square or Fisher's exact test for categorical variables.

^c P-values < 0.05 are significant.

of Health in effectively controlling hepatitis B and striving to meet the WHO global health goals for hepatitis C by 2030, thereby improving liver health in society, should not be overlooked. It is important to note that studies suggest that in cirrhosis patients, the anti-HBs titer is very low, especially after eight months (16).

Patients with cirrhosis exhibited ascites, esophageal varices, and hepatic encephalopathy as the most prevalent complications. Similarly, prior literature has identified these conditions as major complications of cirrhosis that may impact the quality of life and survival of affected individuals (17). The prevalence of ascites and hepatic encephalopathy was found to be lower in the second period of our study. As mentioned previously, these improvements may be attributed to enhanced disease management; moreover, with the implementation of more effective guidelines and follow-up procedures, patient recovery and the faster diagnosis of disease complications have improved over the years. Cirrhosis trends have improved worldwide, partly due to the effectiveness of available therapies for the prevention and treatment of HBV and HCV. This is evidenced by the thirty-year decline in liver disease mortality rates worldwide (4). However, HBV and HCV continue to be major causes of cirrhosis worldwide, particularly in low-income countries (18).

Our findings also indicate that autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, and NAFLD were more prevalent among women. Notably, the prevalence of NAFLD was higher among patients in the second period compared to the first period. Therefore, it is imperative to

implement cost-effective strategies for maintaining screening and management of viral hepatitis and achieving early detection and prevention of cirrhosis caused by alcohol-related liver diseases and NAFLD/NASH.

Patients with cirrhosis require long-term treatment, even though liver transplantation may be the sole treatment option (19). In 2017, cirrhosis resulted in 1.32 million deaths worldwide, with approximately twothirds occurring in men and one-third in women (4). In the current investigation, mortality and transplantation rates were comparatively greater among patients who were registered in the first period than those registered during the subsequent period, which can be attributed in part to the relatively longer duration of follow-up in this cohort. Furthermore, the mortality following liver transplantation was significantly lower in the second period, which could be due to improvements in organ preservation and matching, surgical techniques, and the prevention and management of complications.

Our study encountered several limitations. The underreporting of alcohol intake in the present study is likely influenced by cultural and religious considerations. potentially leading to an underestimation of its contribution to the prevalence of cirrhosis. Additionally, the observed differences among patients registered in two distinct periods may be partly attributed to variations in alcohol consumption, which could have increased over time. Moreover, our inclusion of only patients referred to our clinic may constrain the generalizability of our findings. Evaluating these outcomes in alternative centers with diverse age, sex

Variables	2009 - 2016 (n = 2927)	n Value d	$2017 \cdot 2022 (n = 682)$	n Value d	D Vales e
	2009-2010(11-2937)	P-value	2017-2022 (11-085)	r-value	r-value
		< 0.001	22 (72 5)	0.006	0.620
Male	492 (81.5)		89(79.5)		
remaie	112 (18.5)		23 (20.5)		
HepatitisC		< 0.001		0.001	0.238
Male	276 (81.9)		157 (77.7)		
Female	61 (18.1)		45 (22.3)		
Autoimmune hepatitis		< 0.001		< 0.001	0.048
Male	211 (51.1)		16 (35.6)		
Female	202 (48.9)		29 (64.4)		
РВС		0.494		0.002	0.019
Male	42 (60.9)		1 (12.5)		
Female	27 (39.1)		7 (87.5)		
PSC		0.429		0.016	0.102
Male	92 (61.7)		6 (40.0)		
Female	57 (38.3)		9 (60.0)		
NAFLD/NASH		0.333		0.001	0.320
Male	23 (57.5)		22 (46.8)		
Female	17 (42.5)		25 (53.2)		
Wilson		0.149		1.000	0.464
Male	50 (57.5)		6 (75.0)		
Female	37 (42.5)		2 (25.0)		
Alcohol-related		< 0.001		< 0.001	1.000
Male	69 (97.2)		24 (100.0)		
Female	2 (2.8%)		0(0.0)		
Hemochromatosis		0.630		0.332	0.305
Male	32 (68.1)		5 (100.0)		
Female	15 (31.9)		0(0.0)		
Cryptogenic		< 0.001		0.173	0.246
Male	341(57.9)		80 (63.5)		
Female	248 (42.1)		46 (36.5)		

² Abbreviations: PBC, Primary biliary cholangitis, PSC, Primary sclerosing cholangitis, NAFLD, Non-alcoholic fatty liver disease, NASH, Nonalcoholic steatohepatitis.

^a Values are expressed as No. (%).

^b Between-group differences in variables were determined using the chi-square or Fisher's exact test for categorical variables.

^c P-values < 0.05 are significant.

^d Comparison of sex distribution in each period.

^e Comparison of sex distribution between two period.

distribution, or cultural attributes could yield disparate results.

5.1. Conclusions

In conclusion, patients registered in the second period exhibited better laboratory and clinical outcomes. Viral hepatitis remains the most common cause of cirrhosis in both periods and was more prevalent among men. The epidemiological characteristics of cirrhosis indicate that targeted intervention policies, such as hepatitis B vaccination, have contributed to reducing the progression of cirrhosis.

Supplementary Material

Supplementary material(s) is available here [To read supplementary materials, please refer to the journal website and open PDF/HTML].

Footnotes

Authors' Contribution: Study concept and design: AR. S., and MR. F.; analysis and interpretation of data: H. A., and S. SZ.; H. A., drafting of the manuscript: H. A.; critical revision of the manuscript for important intellectual content: H. A.; H. KJ statistical analysis: H. A, S. SZ, V. A, L. R and GR. S.

Conflict of Interests: The authors declared that they have no conflicts of interest.

Data Availability: Data supporting the results of this study is available from the author (A.R.S), upon reasonable request.

Ethical Approval: We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during the course of this research (IR.SUMS.REC.1394.S200).

Funding/Support: This project was supported by grant number 6568 from Shiraz University of Medical Sciences.

Informed Consent: All the data were anonymized before the processing and participants gave written consent for sharing their data.

References

- Zong Z, Liu J, Wang N, Yang C, Wang Q, Zhang W, et al. Nicotinamide mononucleotide inhibits hepatic stellate cell activation to prevent liver fibrosis via promoting PGE(2) degradation. *Free Radic Biol Med.* 2021;**162**:571-81. [PubMed ID: 33220424]. https://doi.org/10.1016/j.freeradbiomed.2020.11.014.
- Sepanlou S, Safiri S, Bisignano C, Ikuta K, Merat S, Saberifiroozi M, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Gastroenterol Hepatol.* 2020;5:245-66. https://doi.org/10.1016/S2468-1253(19)30349-8.
- Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. *Liver Int.* 2018;38 Suppl 1:2-6. [PubMed ID: 29427496]. https://doi.org/10.1111/liv.13682.
- Cheemerla S, Balakrishnan M. Global Epidemiology of Chronic Liver Disease. *Clin Liver Dis (Hoboken)*. 2021;**17**(5):365-70. [PubMed ID: 34136143]. [PubMed Central ID: PMC8177826]. https://doi.org/10.1002/cld.1061.
- Anushiravani A, Ghajarieh Sepanlou S. Burden of Liver Diseases: A Review from Iran. *Middle East J Dig Dis*. 2019;**11**(4):189-91. [PubMed ID: 31824620]. [PubMed Central ID: PMC6895850]. https://doi.org/10.15171/mejdd.2019.147.
- Rezaei N, Asadi-Lari M, Sheidaei A, Khademi S, Gohari K, Delavari F, et al. Liver cirrhosis mortality at national and provincial levels in Iran between 1990 and 2015: A meta regression analysis. *PLoS One*. 2019;**14**(1). e0198449. [PubMed ID: 30645598]. [PubMed Central ID: PMC6333345]. https://doi.org/10.1371/journal.pone.0198449.

- El-Serag HB, Kanwal F, Feng Z, Marrero JA, Khaderi S, Singal AG, et al. Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. *Gastroenterol.* 2020;**159**(1):376-7. [PubMed ID: 32234536]. [PubMed Central ID: PMC8375364]. https://doi.org/10.1053/j.gastro.2020.03.049.
- Rubin JB, Sundaram V, Lai JC. Gender Differences Among Patients Hospitalized With Cirrhosis in the United States. *J Clin Gastroenterol.* 2020;54(1):83-9. [PubMed ID: 30807399]. [PubMed Central ID: PMC6706332]. https://doi.org/10.1097/MCG.000000000001192.
- 9. Dong MH, Saab S. Complications of cirrhosis. *Dis Mon.* 2008;**54**(7):445-56. [PubMed ID: 18570914]. https://doi.org/10.1016/j.disamonth.2008.03.006.
- Fowler C. Management of patients with complications of cirrhosis. *Nurse Pract.* 2013;**38**(4):14-21. quiz 22-3. [PubMed ID: 23454902]. https://doi.org/10.1097/01.NPR.0000427610.76270.45.
- Im PK, Millwood IY, Kartsonaki C, Guo Y, Chen Y, Turnbull I, et al. Alcohol drinking and risks of liver cancer and non-neoplastic chronic liver diseases in China: a 10-year prospective study of 0.5 million adults. *BMC Med.* 2021;**19**(1):216. [PubMed ID: 34530818]. [PubMed Central ID: PMC8447782]. https://doi.org/10.1186/s12916-021-02079-1.
- Liu Y, Dai M, Bi Y, Xu M, Xu Y, Li M, et al. Active smoking, passive smoking, and risk of nonalcoholic fatty liver disease (NAFLD): a population-based study in China. *J Epidemiol.* 2013;23(2):115-21. [PubMed ID: 23399520]. [PubMed Central ID: PMC3700247]. https://doi.org/10.2188/jea.je20120067.
- Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, et al. Metabolic risk factors and incident advanced liver disease in nonalcoholic fatty liver disease (NAFLD): A systematic review and metaanalysis of population-based observational studies. *PLoS Med.* 2020;17(4). e1003100. [PubMed ID: 32353039]. [PubMed Central ID: PMC7192386]. https://doi.org/10.1371/journal.pmed.1003100.
- Sajja KC, Mohan DP, Rockey DC. Age and ethnicity in cirrhosis. J Investig Med. 2014;62(7):920-6. [PubMed ID: 25203153]. [PubMed Central ID: PMC4172494]. https://doi.org/10.1097/JIM.00000000000106.
- Mohammed H, Eshetie A, Melese D. Prevalence of hepatitis B virus and associated risk factors among adults patients at Dessie referral and Kemise general hospitals in northeastern Ethiopia. *Health Sci Rep.* 2022;5(3). e659. [PubMed ID: 35620544]. [PubMed Central ID: PMC9125169]. https://doi.org/10.1002/hsr2.659.
- Herta T, Petroff D, Engelmann C, Herber A, Aehling N, Scheuermann U, et al. Hepatitis B Vaccination in Patients with Liver Cirrhosis Evaluated for Liver Transplantation - A Simple Intervention Ensures High Adherence. Ann Transplant. 2019;24:527-31. [PubMed ID: 31515466]. [PubMed Central ID: PMC6755938]. https://doi.org/10.12659/AOT.917198.
- Liu YB, Chen MK. Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions. *World J Gastroenterol*. 2022;**28**(41):5910-30. [PubMed ID: 36405106]. [PubMed Central ID: PMC9669831]. https://doi.org/10.3748/wjg.v28.i41.5910.
- Zhai M, Long J, Liu S, Liu C, Li L, Yang L, et al. The burden of liver cirrhosis and underlying etiologies: results from the global burden of disease study 2017. *Aging (Albany NY)*. 2021;**13**(1):279-300. [PubMed ID: 33436531]. [PubMed Central ID: PMC7835066]. https://doi.org/10.18632/aging.104127.
- Pedroso-Flaquet P, Alfonso-Sague K, J S. Characterization of Deaths from Cirrhosis of the Liver in Cuba, 1987-2017. *Medicc Rev.* 2020;22(4):35-9. [PubMed ID: 33295318]. https://doi.org/10.37757/MR2020.V22.N4.6.